Lykissas M, Gkiatas I. Use of recombinant human bone morphogenetic protein-2 in spine surgery. World J Orthop 2017; 8(7): 531-535 [PMID: 28808623 DOI: 10.5312/wjo.v8.i7.531]
Corresponding Author of This Article
Marios Lykissas, MD, Department of Spine Surgery, Metropolitan Hospital, Ethnarxou Makariou 9 & El. Venizelou 1, 18547 Athens, Greece. mariolyk@yahoo.com
Research Domain of This Article
Orthopedics
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Orthop. Jul 18, 2017; 8(7): 531-535 Published online Jul 18, 2017. doi: 10.5312/wjo.v8.i7.531
Use of recombinant human bone morphogenetic protein-2 in spine surgery
Marios Lykissas, Ioannis Gkiatas
Marios Lykissas, Department of Spine Surgery, Metropolitan Hospital, 18547 Athens, Greece
Ioannis Gkiatas, Orthopaedic Department, University Hospital of Ioannina, 45500 Ioannina, Greece
Author contributions: Lykissas M performed the majority of the writing, collecting all the bibliography that was used; Gkiatas I performed writing as well as input in writing the paper and designed the outline.
Conflict-of-interest statement: There is no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Marios Lykissas, MD, Department of Spine Surgery, Metropolitan Hospital, Ethnarxou Makariou 9 & El. Venizelou 1, 18547 Athens, Greece. mariolyk@yahoo.com
Telephone: +30-694-4591915 Fax: +30-210-4814887
Received: December 18, 2016 Peer-review started: December 20, 2016 First decision: January 28, 2017 Revised: February 5, 2017 Accepted: April 18, 2017 Article in press: April 20, 2017 Published online: July 18, 2017 Processing time: 207 Days and 11.8 Hours
Abstract
Bone morphogenetic proteins are osteoinductive factors which have gained popularity in orthopaedic surgery and especially in spine surgery. The use of recombinant human bone morphogenetic protein-2 has been officially approved by the United States Food and Drug Administration only for single level anterior lumbar interbody fusion, nevertheless it is widely used by many surgeons with off-label indications. Despite advantages in bone formation, its use still remains a controversial issue and several complications have been described by authors who oppose their wide use.
Core tip: The use of recombinant human bone morphogenetic protein-2 is widely used in spine surgery not only in approved indications but also in off-label indications. Despite its ability to promote fusion there are many reported disadvantages. That’s why the Yale University Open Data project aims to serve both the patients but also the companies which fund the vast majority of research in medical products.
